131 related articles for article (PubMed ID: 30396934)
1. Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
Kim HM; Jeong I; Kim HJ; Kang SK; Kwon WS; Kim TS; Park KH; Jung M; Soong J; Lin SC; Chung HC; Rha SY
Anticancer Res; 2018 Nov; 38(11):6171-6180. PubMed ID: 30396934
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer.
Jung M; Park KH; Kim HM; Kim TS; Zhang X; Park SM; Beom SH; Kim HS; Cheong JH; Chung HC; Soong J; Lin SC; Rha SY
Gastric Cancer; 2019 Nov; 22(6):1153-1163. PubMed ID: 31098863
[TBL] [Abstract][Full Text] [Related]
3. Nuclear localization of the CK2α-subunit correlates with poor prognosis in clear cell renal cell carcinoma.
Rabjerg M; Guerra B; Oliván-Viguera A; Mikkelsen ML; Köhler R; Issinger OG; Marcussen N
Oncotarget; 2017 Jan; 8(1):1613-1627. PubMed ID: 27906674
[TBL] [Abstract][Full Text] [Related]
4. Casein kinase 2 inhibitor CX-4945 elicits an anti-Warburg effects through the downregulation of TAp73 and inhibits gastric tumorigenesis.
Tang S; Yuan Y; Liu Z; He Y; Pan D
Biochem Biophys Res Commun; 2020 Oct; 530(4):686-691. PubMed ID: 32771361
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of casein kinase 2 prevents growth of human osteosarcoma.
Takahashi K; Setoguchi T; Tsuru A; Saitoh Y; Nagano S; Ishidou Y; Maeda S; Furukawa T; Komiya S
Oncol Rep; 2017 Feb; 37(2):1141-1147. PubMed ID: 27959425
[TBL] [Abstract][Full Text] [Related]
6. Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines.
Hwang DW; So KS; Kim SC; Park KM; Lee YJ; Kim SW; Choi CM; Rho JK; Choi YJ; Lee JC
Pancreas; 2017 Apr; 46(4):575-581. PubMed ID: 28196025
[TBL] [Abstract][Full Text] [Related]
7. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
8. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
So KS; Rho JK; Choi YJ; Kim SY; Choi CM; Chun YJ; Lee JC
Anticancer Res; 2015 Mar; 35(3):1537-42. PubMed ID: 25750308
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
[TBL] [Abstract][Full Text] [Related]
10. Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.
Bollacke A; Nienberg C; Borgne ML; Jose J
J Pharm Biomed Anal; 2016 Mar; 121():253-260. PubMed ID: 26786382
[TBL] [Abstract][Full Text] [Related]
11. CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity.
Masłyk M; Janeczko M; Martyna A; Kubiński K
Mol Cell Biochem; 2017 Nov; 435(1-2):193-196. PubMed ID: 28501934
[TBL] [Abstract][Full Text] [Related]
12. Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.
Trembley JH; Unger GM; Tobolt DK; Korman VL; Wang G; Ahmad KA; Slaton JW; Kren BT; Ahmed K
Mol Cell Biochem; 2011 Oct; 356(1-2):21-35. PubMed ID: 21761204
[TBL] [Abstract][Full Text] [Related]
13. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy.
Ruggeri E; Frezzato F; Mouawad N; Pizzi M; Scarmozzino F; Capasso G; Trimarco V; Quotti Tubi L; Cellini A; Cavarretta CA; Ruocco V; Serafin A; Angotzi F; Danesin N; Manni S; Facco M; Piazza F; Trentin L; Visentin A
Front Immunol; 2024; 15():1393485. PubMed ID: 38807597
[TBL] [Abstract][Full Text] [Related]
15. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of CX-4945 binding to human protein kinase CK2.
Ferguson AD; Sheth PR; Basso AD; Paliwal S; Gray K; Fischmann TO; Le HV
FEBS Lett; 2011 Jan; 585(1):104-10. PubMed ID: 21093442
[TBL] [Abstract][Full Text] [Related]
17. Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.
Wińska P; Skierka K; Łukowska-Chojnacka E; Koronkiewicz M; Cieśla J; Bretner M
Anticancer Res; 2018 Aug; 38(8):4617-4627. PubMed ID: 30061228
[TBL] [Abstract][Full Text] [Related]
18. Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
So KS; Kim CH; Rho JK; Kim SY; Choi YJ; Song JS; Kim WS; Choi CM; Chun YJ; Lee JC
PLoS One; 2014; 9(12):e114000. PubMed ID: 25486409
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.
Bian Y; Han J; Kannabiran V; Mohan S; Cheng H; Friedman J; Zhang L; VanWaes C; Chen Z
Int J Biol Sci; 2015; 11(4):411-22. PubMed ID: 25798061
[TBL] [Abstract][Full Text] [Related]
20. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond.
Kim J; Kim SH
Arch Pharm Res; 2012 Aug; 35(8):1293-6. PubMed ID: 22941473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
